Clinical-stage company Respira Technologies has appointed a new Chief Executive Officer (CEO) to the company.
Brian Quigley will take over as CEO after working as Respira’s Chief Operating Officer (COO) for the past two years.
Quigley previously worked at Altria Group for 16 years where he spent seven years as President & CEO at Altria’s Smokeless and Innovative Products/Vapor Businesses.
Respira is currently developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseases. The company is in the midst of securing financing for clinical trials. It’s hoped that Quigley’s background as a successful business leader and Fortune 150 CEO in the space will help drive Respira to its next phase as it advances to clinical trials.
Respira’s founder, Mario Danek, will transition to the role of Chief Technology Officer (CTO). In this role, Danek will focus on concentrating on inventing and refining its innovative inhalation device across multiple potential indication areas and target markets.
Respira is now attempting to gain a combination product authorisation from the FDA for the first inhalable prescription smoking cessation therapy.